EUVIMEDEUVIMED entdecken
Open Access

Remote Monitoring and Data Collection for Decentralized Clinical Trials

Bobby Daly, Otis W Brawley, Mary K Gospodarowicz, Olufunmilayo I Olopade, Lola Fashoyin-Aje, Victoria Wolodzko Smart, I-Fen Chang, Craig L Tendler, Geoffrey Kim, Charles S Fuchs, Muhammad Shaalan Beg, Lianshan Zhang und 12 weitere

JAMA Network Open · 12.04.2024 · 7 (4) · e246228

DOI: 10.1001/jamanetworkopen.2024.6228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 12.04.2024. Verfasst von Bobby Daly und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Less than 5% of patients with cancer enroll in a clinical trial, partly due to financial and logistic burdens, especially among underserved populations. The COVID-19 pandemic marked a substantial shift in the adoption of decentralized trial operations by pharmaceutical companies.

Objective

To assess the current global state of adoption of decentralized trial technologies, understand factors that may be driving or preventing adoption, and highlight aspirations and direction for industry to enable more patient-centric trials. Design, Setting, and Participants The Bloomberg New Economy International Cancer Coalition, composed of patient advocacy, industry, government regulator, and academic medical center representatives, developed a survey directed to global biopharmaceutical companies of the coalition from October 1 through December 31, 2022, with a focus on registrational clinical trials. The data for this survey study were analyzed between January 1 and 31, 2023. Exposure Adoption of decentralized clinical trial technologies. Main Outcomes and Measures The survey measured (1) outcomes of different remote monitoring and data collection technologies on patient centricity, (2) adoption of these technologies in oncology and all therapeutic areas, and (3) barriers and facilitators to adoption using descriptive statistics.

Results

All 8 invited coalition companies completed the survey, representing 33% of the oncology market by revenues in 2021. Across nearly all technologies, adoption in oncology trials lags that of all trials. In the current state, electronic diaries and electronic clinical outcome assessments are the most used technology, with a mean (SD) of 56% (19%) and 51% (29%) adoption for all trials and oncology trials, respectively, whereas visits within local physician networks is the least adopted at a mean (SD) of 12% (18%) and 7% (9%), respectively. Looking forward, the difference between the current and aspired adoption rate in 5 years for oncology is large, with respondents expecting a 40% or greater absolute adoption increase in 8 of the 11 technologies surveyed. Furthermore, digitally enabled recruitment, local imaging capabilities, and local physician networks were identified as technologies that could be most effective for improving patient centricity in the long term. Conclusions and Relevance These findings may help to galvanize momentum toward greater adoption of enabling technologies to support a new paradigm of trials that are more accessible, less burdensome, and more inclusive.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsClinical Trials as TopicHumansData CollectionMedical Oncology

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York.
  • School of Medicine, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.
  • Medicine and Human Genetics, Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, Illinois.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.
  • Susan G. Komen Foundation, Dallas, Texas.

Förderung

  • NCI NIH HHS

Zitieren

APA

Daly, B., Brawley, O. W., Gospodarowicz, M. K., Olopade, O. I., Fashoyin-Aje, L., Smart, V. W., Chang, I. F., Tendler, C. L., Kim, G., Fuchs, C. S., Beg, M. S., Zhang, L., Legos, J. J., Duran, C. O., Kalidas, C., Qian, J., Finnegan, J., Pilarski, P., Keane, H., …, & Li, B. T. (2024). Remote Monitoring and Data Collection for Decentralized Clinical Trials. JAMA Network Open, 7(4), e246228. https://doi.org/10.1001/jamanetworkopen.2024.6228

Vancouver

Daly B, Brawley OW, Gospodarowicz MK, Olopade OI, Fashoyin-Aje L, Smart VW, et al. Remote Monitoring and Data Collection for Decentralized Clinical Trials. JAMA Network Open. 2024;7(4):e246228. doi:10.1001/jamanetworkopen.2024.6228

BibTeX
@article{Daly2024,
  author = {Daly, Bobby and Brawley, Otis W and Gospodarowicz, Mary K and Olopade, Olufunmilayo I and Fashoyin-Aje, Lola and Smart, Victoria Wolodzko and Chang, I-Fen and Tendler, Craig L and Kim, Geoffrey and Fuchs, Charles S and Beg, Muhammad Shaalan and Zhang, Lianshan and Legos, Jeffrey J and Duran, Cristina Ortega and Kalidas, Chitkala and Qian, Jing and Finnegan, Justin and Pilarski, Piotr and Keane, Harriet and Shen, Johanna and Silverstein, Amy and Wu, Yi-Long and Pazdur, Richard and Li, Bob T},
  title = {Remote Monitoring and Data Collection for Decentralized Clinical Trials},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {4},
  pages = {e246228},
  doi = {10.1001/jamanetworkopen.2024.6228}
}
Kostenlos starten →